TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06306456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW/6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagrisso
Description: Oral, 80mg QD
Study: NCT05008991

Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.

Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
Study: NCT05210790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rusfertide
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rusfertide
Description: Experimental drug
Study: NCT06022016

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: For each person (index case or related) included in this study:
Description: * an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed.
Study: NCT04796246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leap Motion Controller
Description: Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller
Description: Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
Study: NCT05984355

Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary

Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary

Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
Study: NCT05874180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6013
Description: Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6013
Description: Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Study: NCT06466174

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1 to Probiotic A
Description: 42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic A to Placebo 1
Description: 42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2 to Probiotic B
Description: 42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic B to Placebo 2
Description: 42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
Study: NCT05922371

Intervention type: DIAGNOSTIC_TEST
Intervention: NuQ H3.1 Nucleosome Assay
Description: Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.

Intervention type: DIAGNOSTIC_TEST
Intervention: NuQ H3.1 Nucleosome Assay
Description: Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
Study: NCT06148298

Intervention type: OTHER
Intervention: Non-Human Subject Research study.
Description: This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
Study: NCT05999227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: A fibroblast activation protein (FAP) -targeted PET imaging agent
Study: NCT06240949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional Release Technique
Description: Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Pressure Technique
Description: Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
Study: NCT05999227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: A general glucose metabolism imaging agent
Study: NCT04932980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: administration of anti-VEGF Aflibercept (Eylea)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brolucizumab
Description: administration of anti-VEGF Brolucizumab (Beovu)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early treat and extend (T&E)
Description: extension of treatment intervals (T\&E) from the beginning of treatment
Study: NCT05933460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement with probiotics, prebiotics, magnesium and saffron extract
Description: A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement with probiotics, prebiotics, magnesium
Description: A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
Study: NCT06236386

Intervention type: OTHER
Group type: OTHER
Intervention: VR Experience
Description: VR headset and video experience.
Study: NCT05447208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study: NCT06056583

Intervention type: DRUG
Group type: OTHER
Intervention: Cimetidine 200 MG
Description: Cimetidine will serve as the probe drug
Study: NCT04932980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early treat and extend (T&E)
Description: extension of treatment intervals (T\&E) from the beginning of treatment
Study: NCT06159972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
Study: NCT06284655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group-based combined with innovative technology education
Description: The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Treatment as usual.
Study: NCT05142826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relative Age Effect Intervention
Description: School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relative Age Effect Intervention
Description: School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School as Usual
Description: Interventions and supports as provided through usual care
Study: NCT04845607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Injection
Description: Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
Study: NCT04929327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self etch Pit and fissure sealant application (prevent seal)
Description: Sealing deep pits and fissures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting
Description: Sandblasting before Sealing deep pits and fissures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total etch resin based sealant ultraseal xt
Description: Sealing deep pits and fissures
Study: NCT04795037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004, Single dose
Description: Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004, Multiple doses
Description: Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CU06-1004, oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CU06-1004, oral capsule
Study: NCT06254040

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixture of extracts and DHA
Description: Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
Study: NCT05759858

Intervention type: OTHER
Intervention: None of intervention
Description: None of the interventions was applied.
Study: NCT06453759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei
Description: The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts.
Study: NCT04926948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06027008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation
Description: MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4).
Study: NCT06009835

Intervention type: OTHER
Intervention: Recommended treatment plan
Description: Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
Study: NCT03826758

Intervention type: OTHER
Group type: OTHER
Intervention: E-DYNAMIC Clinical Decision Support
Description: Clinical decision support system
Study: NCT04223882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Management of Stress
Description: Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: outpatient medical appointments
Study: NCT05746468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological assessment and intervention
Description: The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-based Mindfulness intervention
Description: The control group will receive audio recordings of how to practice mindfulness at home.
Study: NCT05612009

Intervention type: COMBINATION_PRODUCT
Intervention: Toothpastes
Description: Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride).
Study: NCT06091176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amicomed®
Description: This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Placebo
Description: Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
Study: NCT06102473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
Study: NCT06334640

Intervention type: DIAGNOSTIC_TEST
Intervention: Three questionaires
Description: Berlin, Pittsburgh and Epworth tests administered during study visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Three questionaires
Description: Berlin, Pittsburgh and Epworth tests administered during study visit
Study: NCT04430439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial stress
Description: The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control non-stress
Description: Participants will have a relaxed 15 minute conversation with a familiar research team member.
Study: NCT06098534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospi'Senior
Description: The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional room
Description: The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair.